Table 3. p16 status in relation to patient age, N status and 2- and 5-year survival, respectively.
p16 QS | Patients aged ⩽40 years | Patients aged 41–65 years | Patients aged >65 years | N0 | N+ | 2-year survival | 5-year survival | |
---|---|---|---|---|---|---|---|---|
0 | 12 (75%) | 25 (66%) | 36 (66%) | 58 (72%) | 15 (52%) | 44 (75%) | 28 (76%) | 73 (67%) |
1–5 | 2 (12.5%) | 9 (24%) | 10 (18%) | 15 (19%) | 6 (21%) | 9 (15%) | 5 (13%) | 21 (19%) |
6–18 | 2 (12.5%) | 4 (10%) | 9 (16%) | 7 (9%) | 8 (27%) | 6 (10%) | 4 (11%) | 15 (14%) |
Total | 16 | 38 | 55 | 80 | 29 | 59/105 | 37/89 | 109 |
Abbreviation: N=nodal metastasis; QS=quick score. Concerning 2-year survival, 4 patients had not been followed that long, and in the analysis of 5-year survival, 20 patients had too short follow-up.